What GIP and GLP-1 mean
GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are incretin hormones released after eating. They influence insulin release, appetite and digestion.
Tirzepatide activates both receptors. That dual mechanism distinguishes it from GLP-1-only medications; it does not make it the right choice for everyone.
Approved products and compounded preparations
Approved tirzepatide products have defined indications and labeling. Compounded preparations are not FDA approved and should not be marketed as equivalent. A past shortage does not by itself permit current compounding.
Clinical-trial outcomes for approved products are not outcomes Level Health has measured.
Part of a plan
If treatment is appropriate, your care includes follow-up visits, side-effect check-ins and practical coaching around food, movement and sleep.
Important safety information
- Common effects can include nausea, diarrhea, vomiting, constipation, decreased appetite and indigestion.
- Approved labeling carries a boxed warning about thyroid C-cell tumors; not used with a personal or family history of medullary thyroid carcinoma or MEN 2.
- Labeling also discusses pancreatitis, gallbladder disease, hypoglycemia with certain medications, kidney problems and allergic reactions.
- Can reduce the effectiveness of oral hormonal contraceptives for a period; discuss with your clinician.
This summary is not complete. Refer to the official product labeling and talk with your clinician.
Contact a clinician or seek care if you have
- Severe abdominal pain that does not go away
- Signs of an allergic reaction
- A neck lump, trouble swallowing or persistent hoarseness
- Signs of dehydration
For a medical emergency, call 911.
Sources
Clinical review: pending. Medical copy must be reviewed by a licensed clinician before publication.